TY - JOUR
T1 - Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations
AU - Alvarado, Angel T.
AU - Ybañez-Julca, Roberto
AU - Muñoz, Ana María
AU - Tejada-Bechi, César
AU - Cerro, Roberto
AU - Quiñones, Luis Abel
AU - Varela, Nelson
AU - Alvarado, César André
AU - Alvarado, Erick
AU - Bendezú, María R.
AU - García, Jorge A.
N1 - Funding Information:
Latin American Society of Pharmacogenomics and Personalized Medicine and Latin American Network for the Implementation and Validation of Clinical Pharmacogenomics Guidelines (RELIVAF-CYTED), Madrid, Spain.
Publisher Copyright:
© 2021
PY - 2021
Y1 - 2021
N2 - Wild type genotypes (CYP2D6) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4. The percentages of genotypes described were 97% CYP2D6*1/*1 and 3.0% CYP2D6*1/*3; 90.60% for CYP2D6*1/*1, 8.55% CYP2D6*1/*4 and 0.85% CYP2D6*4/*4. The allelic frequencies of CYP2D6*3 in the Lima subpopulations were 0.022 and 0.010 for Junin; CYP2D6*4 of 0.048, 0.060, and 0.050 for residents of Lima, Junín, and Tacna, respectively. The Hardy-Weinberg equilibrium test for the studied population showed that both frequencies are in equilibrium, p 〜.05. The metabolizer phenotype was inferred according to the genotypes: 11.54% were classified as intermediate metabolizers (*1/*3 or *1/*4) and 0.85% as poor metabolizers (*4/*4). It is concluded that the frequencies of the CYP2D6*3 and CYP2D6*4 alleles are low for the Peruvian mestizo population compared to the Latin American and tricontinental population, due to their natural population evolution, which is manifested by their decreased metabolic activity, the same that is relevant in clinical practice.
AB - Wild type genotypes (CYP2D6) and their allelic variants have been described in a sample of a Peruvian mestizo population. The global allele frequency was 0.015 for CYP2D6*3 and 0.051 for CYP2D6*4. The percentages of genotypes described were 97% CYP2D6*1/*1 and 3.0% CYP2D6*1/*3; 90.60% for CYP2D6*1/*1, 8.55% CYP2D6*1/*4 and 0.85% CYP2D6*4/*4. The allelic frequencies of CYP2D6*3 in the Lima subpopulations were 0.022 and 0.010 for Junin; CYP2D6*4 of 0.048, 0.060, and 0.050 for residents of Lima, Junín, and Tacna, respectively. The Hardy-Weinberg equilibrium test for the studied population showed that both frequencies are in equilibrium, p 〜.05. The metabolizer phenotype was inferred according to the genotypes: 11.54% were classified as intermediate metabolizers (*1/*3 or *1/*4) and 0.85% as poor metabolizers (*4/*4). It is concluded that the frequencies of the CYP2D6*3 and CYP2D6*4 alleles are low for the Peruvian mestizo population compared to the Latin American and tricontinental population, due to their natural population evolution, which is manifested by their decreased metabolic activity, the same that is relevant in clinical practice.
KW - Genetic polymorphism
KW - Metabolic phenotype
KW - Peruvian mestizo population
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=85122560518&partnerID=8YFLogxK
U2 - 10.3897/pharmacia.68.e75165
DO - 10.3897/pharmacia.68.e75165
M3 - Artículo
AN - SCOPUS:85122560518
SN - 0428-0296
VL - 68
SP - 891
EP - 898
JO - Pharmacia
JF - Pharmacia
IS - 4
ER -